Phathom Pharmaceuticals (PHAT) Cash & Equivalents (2018 - 2026)

Phathom Pharmaceuticals (PHAT) has reported Cash & Equivalents for 9 consecutive years, with $185.3 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Cash & Equivalents rose 21.59% year-over-year to $185.3 million; the TTM figure through Jun 2026 stood at $185.3 million (up 21.59% YoY), while the FY2025 annual figure was $132.8 million, down 55.74% from the prior year.
• Cash & Equivalents improved to $185.3 million in Q2 2026 per PHAT's latest filing, from $183.8 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $384.3 million in Q4 2023 and bottomed at $130.1 million in Q1 2023.
• Historically, Cash & Equivalents has averaged $218.3 million across 5 years, with a median of $202.6 million in 2022.
• Annual changes were most pronounced in 2024 — Cash & Equivalents soared 149.92% — and 2025, when it plunged 59.11%.
• Phathom Pharmaceuticals' Cash & Equivalents stood at $155.9 million in 2022, then jumped by 146.49% to $384.3 million in 2023, then decreased by 21.89% to $300.1 million in 2024, then sank by 55.74% to $132.8 million in 2025, then surged by 39.53% to $185.3 million in 2026.
• Business Quant data shows PHAT's Cash & Equivalents at $185.3 million in Q2 2026, $183.8 million in Q1 2026, and $132.8 million in Q4 2025.